,
,
,
,
,
,
,
,
,
,
, Annexe, vol.1
, Annexe 2. Caractéristiques cliniques de la cohorte CA
,
The 2015 World Health Organization Classification of Lung Tumors, J Thorac Oncol. 1 sept, vol.10, issue.9, pp.1243-60, 2015. ,
Molecular and cellular biology of neuroendocrine lung tumors: Evidence for separate biological entities, Biochim Biophys Acta BBA -Rev Cancer. déc, vol.1826, issue.2, pp.255-71, 2012. ,
Small cell carcinoma of the lung and large cell neuroendocrine carcinoma interobserver variability, Histopathology. févr, vol.56, issue.3, pp.356-63, 2010. ,
Current Treatments for Surgically Resectable, Limited-Stage, and Extensive-Stage Small Cell Lung Cancer, The Oncologist. déc, vol.22, issue.12, pp.1510-1517, 2017. ,
Pulmonary Large-Cell Neuroendocrine Carcinoma: From Epidemiology to Therapy, J Thorac Oncol. août, vol.10, issue.8, pp.1133-1174, 2015. ,
Most high-grade neuroendocrine tumours of the lung are likely to secondarily develop from pre-existing carcinoids: innovative findings skipping the current pathogenesis paradigm, Virchows Arch. avr, vol.472, issue.4, pp.567-77, 2018. ,
NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas, Int J Cancer. 15 févr, vol.138, issue.4, pp.927-965, 2016. ,
New Insights into the Molecular Characteristics of Pulmonary Carcinoids and Large Cell Neuroendocrine Carcinomas, and the Impact on Their Clinical Management, J Thorac Oncol. juin, vol.13, issue.6, pp.752-66, 2018. ,
High-grade Neuroendocrine Carcinoma of the Lung With Carcinoid Morphology: A Study of 12 Cases, Am J Surg Pathol. févr, vol.41, issue.2, pp.263-70, 2017. ,
Ki-67 Antigen in Lung Neuroendocrine Tumors: Unraveling a Role in Clinical Practice, J Thorac Oncol. mars, vol.9, issue.3, pp.273-84, 2014. ,
WHO Classification of Tumours of Endocrine Organs ,
Classificat ion-Of-Tumours/Who-Classification-Of-Tumours-Of-Endocrine, 2017. ,
Grading of Well-differentiated Pancreatic Neuroendocrine Tumors Is Improved by the Inclusion of Both Ki67 Proliferative Index and Mitotic Rate, Am J Surg Pathol, vol.37, issue.11, pp.1671-1678, 2013. ,
Pancreatic Neuroendocrine Tumors: Update on the New World Health Organization Classification, vol.22, pp.7-29, 2017. ,
The Clinicopathologic Heterogeneity of Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: Morphological Differentiation and Proliferation Identify Different Prognostic Categories, Neuroendocrinology, vol.104, issue.1, pp.85-93, 2017. ,
Treatment Response and Outcomes of Grade 3 Pancreatic Neuroendocrine Neoplasms Based on Morphology: Well Differentiated Versus Poorly Differentiated, Pancreas. mars, vol.46, issue.3, pp.296-301, 2017. ,
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer, Nat Genet, vol.44, issue.10, pp.1104-1114, 2012. ,
Comprehensive genomic profiles of small cell lung cancer, Nature. août, vol.524, issue.7563, pp.47-53, 2015. ,
Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets, Clin Cancer Res Off J Am Assoc Cancer Res. 15 juill, vol.22, issue.14, pp.3618-3647, 2016. ,
Small Cell and Large Cell Neuroendocrine Carcinomas of the Pancreas are Genetically Similar and Distinct From Welldifferentiated Pancreatic Neuroendocrine Tumors, Am J Surg Pathol. févr, vol.36, issue.2, pp.173-84, 2012. ,
Massive parallel sequencing and digital gene expression analysis reveals potential mechanisms to overcome therapy resistance in pulmonary neuroendocrine tumors, J Cancer, vol.7, issue.15, pp.2165-72, 2016. ,
DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors, Science. 4 mars, vol.331, issue.6021, pp.1199-203, 2011. ,
Whole-genome landscape of pancreatic neuroendocrine tumours, Nature. mars, vol.543, issue.7643, pp.65-71, 2017. ,
A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal, Mod Pathol, vol.31, issue.12, pp.1770-86, 2018. ,
Neuroendocrine Neoplasms: Dichotomy, Origin and Classifications, Visc Med, vol.33, pp.324-354, 2017. ,
, WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart
Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas, Clin Cancer Res. 15 févr, vol.22, issue.4, pp.1011-1018, 2016. ,
Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors, Mod Pathol. juill, vol.25, issue.7, pp.1033-1042, 2012. ,
Study of clinicopathological features, hormone immunoexpression, and loss of ATRX and DAXX expression in pancreatic neuroendocrine tumors ,
, Scand J Gastroenterol. 2 août, vol.51, issue.8, pp.994-1003, 2016.
Surgery Versus Chemotherapy and Radiotherapy For Early and Locally Advanced Small Cell Lung Cancer: A Propensity-Matched Analysis of Survival, Lung Cancer. juill, vol.109, pp.78-88, 2017. ,
Large-Cell Neuroendocrine Carcinoma of the Lung: An Aggressive Neuroendocrine Lung Cancer, Semin Thorac Cardiovasc Surg. sept, vol.18, issue.3, pp.206-216, 2006. ,
Reproducibility of neuroendocrine lung tumor classification, Hum Pathol. mars, vol.29, issue.3, pp.272-281, 1998. ,
Morphometry Confirms the Presence of Considerable Nuclear Size Overlap Between "Small Cells" and "Large Cells" in High-Grade Pulmonary Neuroendocrine Neoplasms, Am J Clin Pathol, vol.116, issue.4, pp.466-72, 2001. ,
Neuroendocrine tumours-challenges in the diagnosis and classification of pulmonary neuroendocrine tumours, J Clin Pathol, vol.66, issue.10, pp.862-871, 2013. ,
High-grade Neuroendocrine Carcinoma of the Lung With Carcinoid Morphology: A Study of 12 Cases, Am J Surg Pathol. févr, vol.41, issue.2, pp.263-70, 2017. ,
Frequent mutations in chromatin-remodeling genes in pulmonary carcinoids, Nat Commun. 27 mars, vol.5, p.3518, 2014. ,
Are G3 ENETS neuroendocrine neoplasms heterogeneous? Endocr Relat Cancer, vol.20, pp.649-57, 2013. ,
Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms, Endocr Relat Cancer. août, vol.22, issue.4, pp.657-64, 2015. ,
Well-differentiated pancreatic neuroendocrine tumours (PanNETs) and poorly differentiated pancreatic neuroendocrine carcinomas (PanNECs): concepts, issues and a practical diagnostic approach to high-grade (G3) cases, Histopathology. janv, vol.72, issue.1, pp.168-77, 2018. ,
A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas, Am J Surg Pathol. sept, vol.40, issue.9, pp.1192-202, 2016. ,
p53: a frequent target for genetic abnormalities in lung cancer. Science, vol.246, pp.491-495, 1989. ,
Molecular genetics of small cell lung carcinoma, Semin Oncol. avr, vol.28, issue.2, pp.3-13, 2001. ,
Variable mutations of the RB gene in small-cell lung carcinoma, Oncogene. nov, vol.5, issue.11, pp.1713-1720, 1990. ,
Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors, Nat Commun, vol.9, issue.13, 2018. ,
Classification of pulmonary neuroendocrine tumors: new insights. Transl Lung Cancer Res, vol.6, pp.513-542, 2017. ,
Limited role of Ki-67 proliferative index in predicting overall short-term survival in patients with typical and atypical pulmonary carcinoid tumors, Mod Pathol Off J U S Can Acad Pathol Inc. sept, vol.25, issue.9, pp.1258-64, 2012. ,
Objective Quantification of the Ki67 Proliferative Index in Neuroendocrine Tumors of the Gastroenteropancreatic System: A Comparison of Digital Image Analysis With Manual Methods, Am J Surg Pathol. déc, vol.36, issue.12, pp.1761-70, 2012. ,
Calculation of the Ki67 index in pancreatic neuroendocrine tumors: a comparative analysis of four counting methodologies, Mod Pathol Off J U S Can Acad Pathol Inc. mai, vol.28, issue.5, pp.686-94, 2015. ,
Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update, J Clin Oncol, vol.33, issue.30, pp.3488-515, 2015. ,
Chemotherapy for pulmonary large cell neuroendocrine carcinomas: does the regimen matter?, Eur Respir J. juin, vol.49, issue.6, p.1601838, 2017. ,
Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes, Clin Lung Cancer. sept, vol.17, issue.5, pp.121-130, 2016. ,
Everolimus with paclitaxel and carboplatin as first-line treatment for metastatic large-cell neuroendocrine lung carcinoma: a multicenter phase II trial, Ann Oncol. 1 août, vol.28, issue.8, pp.1898-902, 2017. ,
, Molecular Subtypes of Pulmonary Large-cell Neuroendocrine Carcinoma Predict Chemotherapy Treatment Outcome | Clinical Cancer Research